PHC Holdings (PHCCF) Fair Value & Analysis
Healthcare · US · Market cap $937M
Fair value as of: Jun 24, 2026
Analysis
PHC Holdings (PHCCF) currently trades at $7.41, while our model-based Fair Value estimate is $7.51 — implying the stock looks roughly 1.3% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
About the company
PHC Holdings Corporation, together with its subsidiaries, provides healthcare digital and precision technology solutions in Japan, Europe, North America, and internationally. The company operates in three segments: Diabetes Management; Healthcare Solutions; and Diagnostic and Life Sciences. It offers precision anatomical pathology for cancer, including tissue processors, digital pathology, and histology consumables; cell growth and preservation, such as CFC-free ultra-low temperature freezers, CO2 incubators, and live cell metabolic analyzer and cell expansion bioreactor system; and diagnostic testing comprising clinical testing, diagnostic reagents, and digital diabetes management solutions. The company also provides patient record and billing solutions, which include electronic medical record systems and receipt systems, systems for pharmacies, and wellness and prevention; diabetes management technology, such as blood and continuous glucose monitoring systems; and medical device a…
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is PHC Holdings (PHCCF) undervalued?
What is the fair value of PHCCF?
What is the quality score of PHCCF?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.